Merck & Company Inc. — KEYTRUDA and KEYTRUDA QLEX · Platinum-Resistant Recurrent Ovarian Cancer.
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (8/27/25) through T+5. Run-up high $121.93 on 2/6/26, low $77.6 on 10/1/25 (T-120 to T-1). FDA decision 2/11/26. Historical price action, not a forecast.